Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Erälinna JP[au]:

Ambient air quality and occurrence of multiple sclerosis relapse. Oikonen M et al. Neuroepidemiology. (2003)

MxA protein assay for optimal monitoring of IFN-beta bioactivity in the treatment of MS patients. Vallittu AM et al. Acta Neurol Scand. (2008)

[Vaccinations and neurological disease]. Erälinna JP et al. Duodecim. (2010)

Search results

Items: 27

1.

[Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].

Soilu-Hänninen M, Päivärinta M, Sonninen P, Parkkola R, Vuorinen T, Erälinna JP.

Duodecim. 2013;129(7):765-70. Finnish.

PMID:
23720945
2.

Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.

Sorensen PS, Lycke J, Erälinna JP, Edland A, Wu X, Frederiksen JL, Oturai A, Malmeström C, Stenager E, Sellebjerg F, Sondergaard HB; SIMCOMBIN study investigators.

Lancet Neurol. 2011 Aug;10(8):691-701. doi: 10.1016/S1474-4422(11)70144-2.

PMID:
21742556
3.

Temporal relationship between environmental influenza A and Epstein-Barr viral infections and high multiple sclerosis relapse occurrence.

Oikonen M, Laaksonen M, Aalto V, Ilonen J, Salonen R, Erälinna JP, Panelius M, Salmi A.

Mult Scler. 2011 Jun;17(6):672-80. doi: 10.1177/1352458510394397. Epub 2011 Jan 6.

PMID:
21212088
4.

[Vaccinations and neurological disease].

Erälinna JP.

Duodecim. 2010;126(7):803-9. Review. Finnish.

PMID:
20597329
5.

[Update on current care guidelines: diagnostics, treatment and rehabilitation of multiple sclerosis].

Elovaara I, Atula S, Erälinna JP, Färkkilä M, Pirttilä T, Remes A, Ruutiainen J, Varis T; Suomalaisen Lääkäriseuran Duodecimin; Suomen Neurologisen Yhdistyksen Asettama Työryhmä.

Duodecim. 2010;126(2):199-200. Finnish.

PMID:
20405605
6.

Beta-interferon protects multiple sclerosis patients against enhanced susceptibility to infections caused by poor air quality.

Oikonen MK, Erälinna JP.

Neuroepidemiology. 2008;30(1):13-9. doi: 10.1159/000113301. Epub 2008 Jan 17.

PMID:
18204292
7.

MxA protein assay for optimal monitoring of IFN-beta bioactivity in the treatment of MS patients.

Vallittu AM, Erälinna JP, Ilonen J, Salmi AA, Waris M.

Acta Neurol Scand. 2008 Jul;118(1):12-7. Epub 2007 Dec 13.

PMID:
18081914
8.

A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis.

Soilu-Hänninen M, Laaksonen M, Laitinen I, Erälinna JP, Lilius EM, Mononen I.

J Neurol Neurosurg Psychiatry. 2008 Feb;79(2):152-7. Epub 2007 Jun 19.

PMID:
17578859
9.

Multippeliskleroosin hoito kannattaa aloittaa varhain.

Ruutiainen J, Elovaara I, Pirttilä T, Erälinna JP, Färkkilä M, Koivisto K, Reunanen M.

Duodecim. 2006;122(18):2181-2. Finnish. No abstract available.

PMID:
17115639
10.

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.

Neurology. 2006 Sep 26;67(6):944-53.

PMID:
17000959
11.

MxA protein induction in MS patients treated with intramuscular IFNbeta-1a.

Vallittu AM, Salmi AA, Erälinna JP; Finnish Beta-Interferon Study Group.

Neurol Sci. 2006 Feb;26(6):438-43.

PMID:
16601938
12.

Enhancement of Th2 responses to replicative herpes simplex virus type 1 vectors by immunomodulative chemotherapy.

Peltoniemi J, Broberg EK, Nygårdas M, Erälinna JP, Waris M, Hukkanen V.

Int Immunopharmacol. 2006 May;6(5):817-29. Epub 2006 Jan 4.

PMID:
16546713
13.

The efficacy of glatiramer acetate in beta-interferon-intolerant MS patients.

Vallittu AM, Peltoniemi J, Elovaara I, Kuusisto H, Färkkilä M, Multanen J, Erälinna JP.

Acta Neurol Scand. 2005 Oct;112(4):234-7.

PMID:
16146492
14.

Downregulation of VLA-4 on T cells as a marker of long term treatment response to interferon beta-1a in MS.

Soilu-Hänninen M, Laaksonen M, Hänninen A, Erälinna JP, Panelius M.

J Neuroimmunol. 2005 Oct;167(1-2):175-82.

PMID:
16087245
15.

Immunomodulation by roquinimex decreases the expression of IL-23 (p19) mRNA in the brains of herpes simplex virus type 1 infected BALB/c mice.

Peltoniemi J, Broberg EK, Halenius A, Setala N, Eralinna JP, Salmi AA, Roytta M, Hukkanen V.

Clin Exp Immunol. 2004 Aug;137(2):305-12.

16.

Ambient air quality and occurrence of multiple sclerosis relapse.

Oikonen M, Laaksonen M, Laippala P, Oksaranta O, Lilius EM, Lindgren S, Rantio-Lehtimäki A, Anttinen A, Koski K, Erälinna JP.

Neuroepidemiology. 2003 Jan-Feb;22(1):95-9.

PMID:
12566960
17.

Cytokines in experimental herpes simplex virus infection.

Hukkanen V, Broberg E, Salmi A, Erälinna JP.

Int Rev Immunol. 2002 Jul-Oct;21(4-5):355-71. Review.

PMID:
12486819
18.

Semliki Forest virus infection is enhanced in Th1-prone SJL mice but not in Th2-prone BALB/c mice during Linomide-induced immunomodulation.

Peltoniemi J, Setälä N, Broberg E, Röyttä M, Hukkanen V, Salmi AA, Erälinna JP.

J Neuroimmunol. 2002 Nov;132(1-2):83-92.

PMID:
12417437
19.

Herpes simplex virus type 1 infection induces upregulation of interleukin-23 (p19) mRNA expression in trigeminal ganglia of BALB/c mice.

Broberg EK, Setälä N, Erälinna JP, Salmi AA, Röyttä M, Hukkanen V.

J Interferon Cytokine Res. 2002 Jun;22(6):641-51.

PMID:
12162874
20.

[Are vitamins dangerous?].

Laaksonen S, Erälinna JP, Falck B.

Duodecim. 2001;117(2):180-2. Finnish. No abstract available.

PMID:
12092370
21.

Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients.

Vallittu AM, Halminen M, Peltoniemi J, Ilonen J, Julkunen I, Salmi A, Erälinna JP; Finnish Beta-Interferon Study Group.

Neurology. 2002 Jun 25;58(12):1786-90.

PMID:
12084878
22.

Expression of interleukin-4 but not of interleukin-10 from a replicative herpes simplex virus type 1 viral vector precludes experimental allergic encephalomyelitis.

Broberg E, Setälä N, Röyttä M, Salmi A, Erälinna JP, He B, Roizman B, Hukkanen V.

Gene Ther. 2001 May;8(10):769-77.

23.

Selective downregulation of Th1 response by Linomide reduces autoimmunity but increases susceptibility to viral infection in BALB/c and SJL mice.

Erälinna JP, Röyttä M, Hukkanen V, Zinhu D, Salmi AA, Salonen R.

J Neuroimmunol. 1998 Aug 1;88(1-2):165-76.

PMID:
9688338
24.
25.

Physical state of the neuroantigen in adjuvant emulsions determines encephalitogenic status in the BALB/c mouse.

Määttä JA, Erälinna JP, Röyttä M, Salmi AA, Hinkkanen AE.

J Immunol Methods. 1996 Mar 28;190(1):133-41.

PMID:
8601706
26.

Facilitation of experimental allergic encephalomyelitis by irradiation and virus infection: role of inflammatory cells.

Erälinna JP, Soilu-Hänninen M, Röyttä M, Ilonen J, Mäkelä A, Salonen R.

J Neuroimmunol. 1994 Nov;55(1):81-90.

PMID:
7962484
27.

Semliki Forest virus infects mouse brain endothelial cells and causes blood-brain barrier damage.

Soilu-Hänninen M, Erälinna JP, Hukkanen V, Röyttä M, Salmi AA, Salonen R.

J Virol. 1994 Oct;68(10):6291-8.

Supplemental Content

Loading ...
Support Center